Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Kaoru Ando"'
Autor:
Kaoru Ando, Aoi Takahata, Hayato Tsuchiya, Daisuke Ishigaki, Yo Koyama, Hiroyasu Sukekawa, Toshiaki Tamabuchi, Yusuke Kobari
Publikováno v:
European Heart Journal: Acute Cardiovascular Care. 7:723-731
Background: Left ventricular dysfunction as part of takotsubo syndrome is reversible, and the long-term prognosis appears favorable. However, life-threatening complications are not uncommon during the acute phase, and it remains unclear whether renal
Autor:
Tetsu Watanabe, Takehiko Miyashita, Isao Kubota, Yoichiro Otaki, Tetsuro Shishido, Takanori Arimoto, Satoshi Nishiyama, Kaoru Ando, Takuya Miyamoto, Hiroki Takahashi, Hyuma Daidoji
Publikováno v:
J Atheroscler Thromb
AIM: Because the prevalence of hyperuricemia is lower in females than in males, the association between hyperuricemia and cardiovascular disease has been frequently reported in females. Increased serum uric acid levels are associated with the presenc
Autor:
Hyuma Daidoji, Isao Kubota, Osamu Hirono, Takanori Arimoto, Satoshi Nishiyama, Cherry study investigators, Tetsuro Shishido, Eiichiro Ikeno, Hiroshi Miyawaki, Takehiko Miyashita, Yoichiro Otaki, Tetsu Watanabe, Shigeo Sugawara, Motoyuki Matsui, Kaoru Ando, Yoshinori Yashiro, Takuya Miyamoto, Hiroki Takahashi
Publikováno v:
Journal of cardiology. 70(6)
Background There is a residual risk of coronary heart disease (CHD) despite intensive statin therapy for secondary prevention. The aim of this study was to investigate whether coronary plaque regression and stabilization are reinforced by the additio
Autor:
Tetsu Watanabe, Shinpei Kadowaki, Isao Kubota, Taro Narumi, Tetsuro Shishido, Takanori Arimoto, Satoshi Nishiyama, Akira Funayama, Naoaki Hashimoto, Yoichiro Otaki, Yoshinori Yashiro, Yu Kumagai, Masahiro Wanezaki, Gensai Yamaura, Kaoru Ando, Hyuma Daidoji, Naoto Hashimoto, Tadateru Iwayama, Takuya Miyamoto, Hiroki Takahashi
Publikováno v:
Circulation. 132
Introduction: High intensity statin therapy is established for secondary prevention of coronary heart disease (CHD). However, additional therapy is required to reduce residual risk in CHD patients with aggressive lipid-lowering therapy. Eicosapentaen
Publikováno v:
Canadian Urological Association Journal. 8:931
Carboplatin is often used instead of cisplatin as an alternative treatment for advanced testicular cancer. However, the safety, optimal dose, and optimal duration of this agent are unclear in patients with cardiac complications. We report the safety
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.